
    
      This is a Phase 2, open-label, multicenter, 28 week extension study to evaluate the long-term
      safety and tolerability of ABT-126 in subjects who complete dosing through Week 24 of Study
      M10-985. Up to 410 subjects may participate at approximately 30 sites in several countries.
    
  